The most recent in a series of trials of multiple-drug combinations with the antibody-drug conjugate belantamab mafodotin (Blenrep, GlaxoSmithKline) met its primary end point in an interim analysis, suggesting it might become a standard for relapsed-refractory multiple myeloma (RRMM).
The tested regimen “appears to be effective at first or subsequent relapses for a broad range of patients,” reported Suzanne Trudel, MD, a clinical researcher at the University of Toronto’s